Lilly's Foundayo Pill Approval Intensifies Weight-Loss Pill War
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Eli Lillys Foundayo, a new weight-loss pill, gains FDA approval, sending stocks soaring. This once-daily oral drug, set to hit US pharmacies in April, intensifies competition with Novo Nordisk, whose shares slipped after the news. Both companies have dominated the weight-loss market for two years, with Novos injectables and Lillys Zepbound. Now, the focus shifts to pills, with Novos Rybelsus and Wegovy pill already on the market. Trial data shows Foundayo users losing an average of eleven percent body weight, trailing Zepbounds twenty-two percent. Novos pill form averages around fourteen percent loss. As pills flood the market, this battle is poised to significantly reshape obesity care.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/30f22bf2365a1544